Tiwari, Arun K. http://orcid.org/0000-0001-9209-2456
Zai, Clement C. http://orcid.org/0000-0003-0496-7262
Altar, C. Anthony
Tanner, Julie-Anne
Davies, Paige E.
Traxler, Paul
Li, James
Cogan, Elizabeth S.
Kucera, Matthew T.
Gugila, Ana
Braganza, Nicole
Emmerson, Heather
Zai, Gwyneth
Müller, Daniel J. http://orcid.org/0000-0003-4978-4400
Levitan, Robert
Kloiber, Stefan
Daskalakis, Zafiris J.
Frey, Benicio N. http://orcid.org/0000-0001-8267-943X
Bowen, James M. http://orcid.org/0000-0002-6457-2337
Tarride, Jean-Eric
Tytus, Richard http://orcid.org/0000-0001-8247-8523
Chandrasena, Ranjith
Voudouris, Nicholas
Taylor, Valerie H.
Tempier, Raymond
Sharma, Verinder
Vasudev, Akshya
Dzongowski, Peter
Pliamm, Lew
Greenspoon, Todd
Dechairo, Bryan M.
Kennedy, James L. http://orcid.org/0000-0002-8733-3806
Article History
Received: 11 June 2021
Revised: 13 January 2022
Accepted: 28 January 2022
First Online: 14 March 2022
Change Date: 30 May 2022
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1038/s41398-022-01963-5
Competing interests
: AKT is a co-inventor on a patent for antipsychotic-induced weight gain at the time of this study (U.S. patent no. 10,662,475). CCZ had a patent on antipsychotic-induced weight gain markers at the time of this study. CAA had ownership/partnership in Splice Therapeutics at the time of this study, and also serves on the advisory board for AxoSim Inc. and the board of directors for ASENT. JAT, PED, PT, JL, MTK, and AG were employed by Myriad Neuroscience/Assurex Health at the time of this study. MTK and ESC were employed by Myriad Genetics at the time of this study. DJM was a co-inventor on two patents assessing risk for antipsychotic-induced weight gain at the time of this study and was also a co-investigator on two pharmacogenetic studies where genetic test kits were provided as in-kind contribution by Myriad Neuroscience but did not receive any salary, equity, stocks, or options from any pharmacogenetic companies. SK received research support from the University of Toronto, Department of Psychiatry Academic Scholar Award, the Labatt Family Innovation Fund in Brain Health, and the Canadian Institutes of Health Research (CIHR) at the time of this study, and received honorarium from Empowerpharm for past consultation. JMB and JET received funding and payment from Myriad Neuroscience to conduct the GAPP-MDD trial until the contract was terminated by Myriad Neuroscience. BMD was employed by Myriad Genetics at the time of this study and received salary and stock options. JLK is an unpaid member of the Myriad Neuroscience Scientific Advisory Board. All other authors declare no conflicts of interest.